Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI scans may reveal hidden clues to myeloma relapse risk

NCT ID NCT07746232

Not yet recruiting Knowledge-focused Sponsor: Fondazione EMN Italy Onlus Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This study is looking at whether a special type of whole-body MRI can help predict how well people with multiple myeloma will do after a stem cell transplant. The MRI measures changes in bone marrow and fat content in the bones, which might indicate if the cancer is more likely to come back. By following patients over time, researchers hope to see if these imaging markers can identify those who need closer monitoring or different treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Diffusion-weighted whole-body MRI (DW-MRI) and fat fraction measurement
What this could lead to
If successful, this could establish MRI as a reliable tool to predict which myeloma patients are at higher risk of relapse after transplant, enabling more personalized follow-up and treatment.
What could go wrong
This is an observational study, so it won't test a new treatment. The predictive value of the MRI measures is not yet proven, and results may not change current practice without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • A.O. Spedali Civili di Brescia

    Brescia, Italy

  • A.O.U. Maggiore della Carità

    Novara, Italy

  • A.O.U. di Bologna - Policlinico S. Orsola Malpighi

    Bologna, Italy

  • ASL Roma 1

    Rome, Italy

  • I.R.C.C.S. Ospedale S. Raffaele

    Milan, Italy

  • IRCCS Istituto Tumori "G. Paolo II - U.O.C. Ematologia e Terapia Cellulare

    Bari, Italy

  • Istituto Oncologico Veneto IRCCS - UOC Oncoematologia

    Castelfranco Veneto, Italy

  • Ospedale Classificato Valduce

    Como, Italy

  • Ospedale Niguarda

    Milan, Italy

  • Policlinico S. Matteo Fondazione IRCCS

    Pavia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.